Corvus Pharmaceuticals (CRVS) Retained Earnings: 2022-2025
Historic Retained Earnings for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to -$400.0 million.
- Corvus Pharmaceuticals' Retained Earnings fell 3.92% to -$400.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.0 million, marking a year-over-year decrease of 3.92%. This contributed to the annual value of -$397.0 million for FY2024, which is 18.61% down from last year.
- Corvus Pharmaceuticals' Retained Earnings amounted to -$400.0 million in Q3 2025, which was down 2.61% from -$389.8 million recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Retained Earnings registered a high of -$274.7 million during Q1 2022, and its lowest value of -$400.0 million during Q3 2025.
- In the last 3 years, Corvus Pharmaceuticals' Retained Earnings had a median value of -$344.7 million in 2024 and averaged -$358.1 million.
- Data for Corvus Pharmaceuticals' Retained Earnings shows a maximum YoY declined of 18.61% (in 2024) over the last 5 years.
- Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Retained Earnings stood at -$307.7 million in 2022, then dropped by 8.78% to -$334.7 million in 2023, then declined by 18.61% to -$397.0 million in 2024, then decreased by 3.92% to -$400.0 million in 2025.
- Its Retained Earnings was -$400.0 million in Q3 2025, compared to -$389.8 million in Q2 2025 and -$381.8 million in Q1 2025.